TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Veru ( (VERU) ).
On August 8, 2025, Veru Inc. implemented a 1-for-10 reverse stock split of its common stock, which was approved by shareholders on July 25, 2025. The reverse stock split aims to help Veru regain compliance with Nasdaq’s $1.00 minimum bid price requirement, and it will affect all shareholders uniformly without changing ownership percentages, except for cash payments in lieu of fractional shares.
The most recent analyst rating on (VERU) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.
Spark’s Take on VERU Stock
According to Spark, TipRanks’ AI Analyst, VERU is a Neutral.
Veru’s overall stock score reflects significant operational and financial challenges, with a declining revenue trend and substantial net losses. The bearish technical indicators and negative valuation metrics further weigh down the score. While the earnings call provided some optimism with positive clinical trial results, the immediate need for additional funding poses a financial risk.
To see Spark’s full report on VERU stock, click here.
More about Veru
Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for cardiometabolic and inflammatory diseases. The company’s drug development program includes enobosarm and sabizabulin, which are being developed for weight reduction and treatment of inflammation in atherosclerotic cardiovascular disease, respectively.
Average Trading Volume: 271,980
Technical Sentiment Signal: Sell
Current Market Cap: $52.62M
For an in-depth examination of VERU stock, go to TipRanks’ Overview page.